News
GSK (LSE:GSK) Seeks European Expansion Of RSV Vaccine To Adults 18 And Older
GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV vaccine, Arexvy, to adults aged 18 and older. This announcement likely supported the company's 14% share price increase last month,
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with ...
Researchers tracked RSV vaccine efficacy in 24,972 participants: 12,469 received the Arexvy vaccine, and 12,503 received a placebo before the first RSV season. Of the vaccine recipients ...
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...
Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback